New CIMZIA(R) Data Demonstrates Efficacy For Up To 18 Months In Patients With Crohn’s Disease, With No Dose Escalation

CIMZIA(R) (certolizumab pegol), the first and only PEGylated anti-TNF therapy, has been shown to maintain remission for up to 18 months in patients with Crohn’s disease, according to new data presented at the 15th United European Gastroenterology Week (UEGW). The data also showed that some patients who were re-introduced to CIMZIA after losing clinical response were re-captured with only one additional induction dose and maintained remission with no dose escalation. [click link for full article]

More: continued here

Filed under: Crohn on October 31st, 2007